<![CDATA[Assessing Bleeding and Variceal Risk Before Anti-VEGF Therapy in HCC]]>

<![CDATA[FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease]]>

A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

Conditions : Hepatocellular Carcinoma Interventions : Drug: SHR-8068+ Adebrelimab+ Bevacizumab; Drug: SHR-8068 Placebo+ Adebrelimab Placebo+

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

DurHope phase 2 study: 30 HCC patients with Vp3/4 PVTT received durvalumab + HAIC-FOLFOX. Primary endpoint: 1-yr OS rate. Could this new app

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

Conditions : Liver Cirrhosis Interventions : Drug: Foscenvivint Sponsors : Kiminori Kimura, MD; Japan Agency for Medical Research and Develo

A Study of Combination Therapy in Patients With Resectable Liver Cancer

Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl

<![CDATA[Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists]]>